Nyrada Inc - Annual Report 2021

NYRADA INC (ASX:NYR) 14 Ian Dixon Ph.D. Non-Executive Director, joined the Board in September 2020. Ian Dixon has a Ph.D. in biomedical engineering fromMonash University, an MBA from Swinburne University and professional engineering qualifications. In 2011, Dr. Dixon Co-Founded Cynata Inc, a company that is progressing the commercialisation of what has become the Cymerus technology of ASX-listed Cynata Therapeutics Ltd (ASX-CYP). Dr. Dixon is a co-inventor of the LEAP Technology owned by Exopharm. Dr. Dixon brings to the Board an extensive technical and entrepreneurial background in founding, building and running technology-based companies, in recognising the potential commercial value of early-stage drug development, and in understanding the challenges involved in drug development. Dr. Dixon is also a founder of Exopharm Ltd. During the last three years, Dr. Dixon has served as a director of the following listed companies: Medigard Ltd (ASX:MGZ) and Noxopharm Ltd (ASX:NOX). Interest in shares and options 10,114,033 shares , 5,999,400 Performance Shares and 1,800,000 unlisted options Special responsibilities Member of the Remuneration and Nomination Committee Directorship held in other listed entities (last 3 years) Exopharm Limited (ASX:EX1) - current Noxopharm Limited (ASX:NOX) - resigned on 31 August 2020 Dr. Graham Kelly Ph.D. Founder and Non-Executive Director, joined the Board in August 2017, resigned 8 September 2020. Graham Kelly is a scientist with 50 years’ of experience in drug development in both the academic and biotechnology sectors. Graham is the Founder, CEO and Managing Director of Noxopharm Limited (ASX:NOX), a major shareholder of Nyrada. Graham has also founded two publicly listed drug development companies (Novogen Limited, now Kazia and Marshall Edwards Inc), serving variously as Managing Director and Executive Chairman of those companies. Graham holds a Ph.D. from The University of Sydney, and degrees in Science and Veterinary Science from The University of Sydney. Other current directorships' quoted above are current directorships for ASX listed entities only and excludes directorships of all other types of entities, unless otherwise stated. Former directorships in other listed entities quoted above are directorships held in the last 3 years for ASX listed entities only and excludes directorships of all other types of entities, unless otherwise stated. Company Secretary - David Franks David is a Chartered Accountant, Fellow of the Financial Services Institute of Australia, Fellow of the Governance Institute of Australia, Justice of the Peace, Registered Tax Agent and holds a Bachelor of Economics (Finance and Accounting) from Macquarie University. With over 25 years in finance and governance (including company secretarial and corporate finance), David has been a CFO, company secretary and director for numerous ASX listed and unlisted public and private companies, in a range of industries covering energy retailing, software as a service, transport, financial services, oil and gas / mineral exploration, technology, automotive, software development, wholesale distributions, retail, biotechnology and healthcare. He has acted in these capacities for Top 200 to small-cap companies listed on ASX, including for companies with OTC listings. David is also the Company Secretary of Noxopharm. David is also a Non-Executive Director of Jcurve Solutions Limited (ASX:JCS) and a Director, Principal and shareholder of Automic Group Pty Ltd, a service provider to the Company.